Key Laboratory of Luminescence Analysis and Molecular Sensing (Southwest University), Ministry of Education, School of Materials and Energy and Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Southwest University, Chongqing, 400715, PR China; Chongqing Key Laboratory of Soft-Matter Material Chemistry and Function Manufacturing, Southwest University, Chongqing 400715, PR China.
Institute of Burn Research, Southwest Hospital, State Key Lab of Trauma, Burn and Combined Injury, Chongqing Key Laboratory for Disease Proteomics, Army Medical University (Third Military Medical University), Chongqing, 400038, PR China.
Acta Biomater. 2022 Jul 15;147:299-313. doi: 10.1016/j.actbio.2022.05.046. Epub 2022 May 29.
Despite the diversified therapeutic approaches for malignant tumors, chemotherapy remains the backbone of current cancer treatment. However, conventional chemotherapeutics was found to be associated with deficient recognition of tumor, low uptake efficiency, insolubility, short circulation, poor biocompatibility and low therapeutic outcomes. Herein, the active targeting redox-responsive mannosylated prodrug nanocolloids (HM NCs) were constructed for enhanced chemotherapy of colon cancer. HM NCs were prepared by the covalent cross-linking of 10-hydroxycamptothecin (HCPT) and mannose (MAN) via a redox-responsive cross-linker containing disulfide bonds, and modified with a moderate amount of polyethylene glycol (PEG). The large amount of mannose contained in HM NCs could actively target overexpressed mannose receptors on the surface of cancer cells and enhance cancer cell internalization through mannose receptor-mediated endocytosis. Owing to the combination of active targeting and the enhanced permeability and retention (EPR) passive targeting, HM NCs could effectively accumulate in tumors and high glutathione (GSH) in tumor microenvironment triggered cleavage of redox-responsive bonds and precise drug release. HM NCs exhibited superior antitumor activity both in vitro and in vivo and appreciably extended the mouse survival rate with good biocompatibility. The innovative HM NCs are expected to be conducive to overcoming the limitations of conventional chemotherapy for colon cancer and providing more choices for future clinical translation. STATEMENT OF SIGNIFICANCE: Despite the enhanced permeability and retention effect, the passive targeting can be interfered with by the complex biologic barriers in the body. In this study, an active targeting system (HM NCs) was constructed by covalent cross-linking of mannose and anticancer drug 10-hydroxycamptothecin via redox-responsive disulfide bonds for enhanced colon cancer chemotherapy. Mannosylation could promote hydrophilia and stability for prolonged blood circulation. Mannose could promote tumor recognition and cell internalization via mannose receptor-mediated endocytosis. High glutathione level could trigger the redox-responsive release of anticancer drugs and further induce cell apoptosis via DNA damage. The HM NCs exhibited superior antitumor activity both in vitro and in vivo and appreciably extended the mouse survival rate with good biocompatibility.
尽管恶性肿瘤的治疗方法多种多样,但化疗仍是当前癌症治疗的基础。然而,传统的化疗被发现存在对肿瘤识别不足、摄取效率低、不溶、循环时间短、生物相容性差和治疗效果不佳等问题。在此,构建了主动靶向氧化还原响应性甘露糖化前药纳米胶束(HM NCs)以增强结肠癌的化学治疗。HM NCs 通过含有二硫键的氧化还原响应性交联剂将 10-羟基喜树碱(HCPT)和甘露糖(MAN)共价交联制备而成,并修饰有适量的聚乙二醇(PEG)。HM NCs 中大量的甘露糖可以主动靶向癌细胞表面过表达的甘露糖受体,并通过甘露糖受体介导的内吞作用增强癌细胞内化。由于主动靶向和增强的通透性和保留(EPR)被动靶向的结合,HM NCs 可以有效地在肿瘤中积累,并且肿瘤微环境中的高谷胱甘肽(GSH)触发氧化还原响应键的断裂和精确的药物释放。HM NCs 在体内外均表现出优异的抗肿瘤活性,并显著延长了小鼠的存活率,同时具有良好的生物相容性。创新的 HM NCs 有望有助于克服传统化疗治疗结肠癌的局限性,并为未来的临床转化提供更多选择。
意义声明:尽管具有增强的通透性和保留效应,但被动靶向可能会受到体内复杂的生物屏障的干扰。在这项研究中,通过氧化还原响应性二硫键将甘露糖和抗癌药物 10-羟基喜树碱共价交联构建了主动靶向系统(HM NCs),以增强结肠癌的化学治疗。甘露糖化可以促进亲水性和稳定性,延长血液循环时间。甘露糖可以通过甘露糖受体介导的内吞作用促进肿瘤识别和细胞内化。高谷胱甘肽水平可以触发氧化还原响应性抗癌药物的释放,并通过 DNA 损伤进一步诱导细胞凋亡。HM NCs 在体内外均表现出优异的抗肿瘤活性,并显著延长了小鼠的存活率,同时具有良好的生物相容性。